464 related articles for article (PubMed ID: 30717704)
1. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
König L; Mairinger FD; Hoffmann O; Bittner AK; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A
BMC Cancer; 2019 Feb; 19(1):120. PubMed ID: 30717704
[TBL] [Abstract][Full Text] [Related]
2. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
3. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
Wang K; Xu J; Zhang T; Xue D
Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588
[TBL] [Abstract][Full Text] [Related]
6. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
8. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
10. Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
Kashiwagi S; Asano Y; Takada K; Goto W; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Mar; 42(3):1421-1431. PubMed ID: 35220235
[TBL] [Abstract][Full Text] [Related]
11. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
12. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
[TBL] [Abstract][Full Text] [Related]
13. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
[TBL] [Abstract][Full Text] [Related]
14. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
19. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]